I-Therapeutix Inc. changed its name to Ocular Therapeutix Inc.
President and CEO Amar Sawhney said (PDF) the change is aimed at better reflecting the company’s mission.
Ocular Therapeutix is seeking approval from the Food & Drug Administration for its I-Zip ocular bandage, which is applied as a liquid but morphs into a soft, protective barrier which then breaks down into tears when the therapy is complete.
The company is also developing ocular drug delivery therapies based on the hydrogel technologies Sawhney developed at the University of Texas.
In June, Ocular Therapeutix raised $15 million in a Series C round to help commercialize the I-Zip bandage.